DCM
RYTM icon

Driehaus Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Driehaus Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Sell
129,285
-307,261
-70% -$27.8M 0.08% 255
2026
Q1 		$38M Sell
436,546
-848,676
-66% -$82.5M 0.28% 126
2025
Q4 		$138M Sell
1,285,222
-98,553
-7% -$10.5M 0.93% 13
2025
Q3 		$140M Buy
1,383,775
+113,823
+9% +$10.6M 1% 10
2025
Q2 		$80.2M Sell
1,269,952
-188,070
-13% -$11.5M 0.64% 39
2025
Q1 		$77.2M Buy
1,458,022
+167,047
+13% +$9.27M 0.74% 32
2024
Q4 		$72.3M Sell
1,290,975
-8,515
-0.7% -$470K 0.6% 38
2024
Q3 		$68.1M Buy
1,299,490
+117,120
+10% +$5.61M 0.58% 46
2024
Q2 		$48.5M Buy
1,182,370
+326,865
+38% +$13M 0.47% 66
2024
Q1 		$37.1M Buy
855,505
+256,600
+43% +$11.2M 0.37% 78
2023
Q4 		$27.5M Buy
598,905
+324,381
+118% +$10.2M 0.33% 97
2023
Q3 		$6.29M Buy
274,524
+251,531
+1,094% +$5.63M 0.08% 267
2023
Q2 		$379K Hold
22,993
– – ﹤0.01% 351
2023
Q1 		$410K Hold
22,993
– – 0.01% 343
2022
Q4 		$670K Hold
22,993
– – 0.01% 308
2022
Q3 		$563K Buy
+22,993
New +$428K 0.01% 313

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Driehaus Capital Management's RYTM Position: Q2 2026 in Review

Driehaus Capital Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 70% in Q2 2026, selling an estimated $27.8M and leaving 129,285 shares worth $14.4M. The position accounts for 0.08% of the portfolio, ranked #255.

Driehaus Capital Management first reported a position in RYTM in Q3 2022 and has held it in 16 quarters since. The position peaked at $140M in Q3 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Driehaus Capital Management held 129,285 shares of Rhythm Pharmaceuticals worth $14.4M as of Q2 2026.
  • Driehaus Capital Management sold 307,261 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $27.8M.
  • Rhythm Pharmaceuticals made up 0.08% of Driehaus Capital Management's portfolio in Q2 2026, its #255 holding.
  • Driehaus Capital Management first reported a position in Rhythm Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Driehaus Capital Management's Rhythm Pharmaceuticals position peaked at $140M in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.